The burden of pathogenic variants in clinically actionable genes in a founder population

Founder populations may be enriched with certain genetic variants of high clinical impact compared to nonfounder populations due to bottleneck events and genetic drift. Using exome sequencing (ES), we quantified the load of pathogenic variants that may be clinically actionable in 6136 apparently hea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of medical genetics. Part A 2021-11, Vol.185 (11), p.3476-3484
Hauptverfasser: Lynch, Megan T., Maloney, Kristin A., Pollin, Toni I., Streeten, Elizabeth A., Xu, Huichun, Shuldiner, Alan R., Van Hout, Cristopher V., Gonzaga‐Jauregui, Claudia, Mitchell, Braxton D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3484
container_issue 11
container_start_page 3476
container_title American journal of medical genetics. Part A
container_volume 185
creator Lynch, Megan T.
Maloney, Kristin A.
Pollin, Toni I.
Streeten, Elizabeth A.
Xu, Huichun
Shuldiner, Alan R.
Van Hout, Cristopher V.
Gonzaga‐Jauregui, Claudia
Mitchell, Braxton D.
description Founder populations may be enriched with certain genetic variants of high clinical impact compared to nonfounder populations due to bottleneck events and genetic drift. Using exome sequencing (ES), we quantified the load of pathogenic variants that may be clinically actionable in 6136 apparently healthy adults living in the Lancaster, PA Old Order Amish settlement. We focused on variants in 78 genes deemed clinically actionable by the American College of Medical Genetics and Genomics (ACMG) or Geisinger's MyCode Health Initiative. ES revealed 3191 total variants among these genes including 480 nonsynonymous variants. After quality control and filtering, we applied the ACMG/AMP guidelines for variant interpretation and classified seven variants, across seven genes, as either pathogenic or likely pathogenic. Through genetic drift, all seven variants, are highly enriched in the Amish compared to nonfounder populations. In total, 14.7% of Lancaster Amish individuals carry at least one of these variants, largely explained by the 13% who harbor a copy of a single variant in APOB. Other studies report combined frequencies of pathogenic/likely pathogenic (P/LP) variants in actionable genes between 2.0% and 6.2% in outbred populations. The Amish population harbors fewer actionable variants compared to similarly characterized nonfounder populations but have a higher frequency of each variant identified, offering opportunities for efficient and cost‐effective targeted precision medicine.
doi_str_mv 10.1002/ajmg.a.62472
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_34467620</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2582283529</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3642-5d07e4fdf8809baaed204ac378ab0ebe4375d057dc8957c43f512cbf018df8cf3</originalsourceid><addsrcrecordid>eNqN0c9vFCEUB3BibGyt3jwbEi8muis_Z9jjZqPVpsZLTbwRhnm0bFgYYaZm_3vZH-6hh8YTL_B55PEFoTeUzCkh7JNZb-7mZt4w0bJn6IJKyWZCcf78VDN5jl6WsiaEE9k2L9A5F6JpG0Yu0K_be8DdlHuIODk8mPE-3UH0Fj-Y7E0cC_YR2-Drlglhi40dfYqmC4Crg_2xwS5NsYeMhzRMwezEK3TmTCjw-rheop9fPt-uvs5uflx9Wy1vZpY3gs1kT1oQrndKkUVnDPSMCGN5q0xHoAPB20pk21u1kK0V3EnKbOcIVbXHOn6J3h_uHXL6PUEZ9cYXCyGYCGkqmsmmBsAYp5W-e0TXacqxTleVYkxxyRZVfTwom1MpGZwest-YvNWU6F3iepe4NnqfeOVvj5dO3Qb6E_4XcQXqAP5Al1yxHqKFEyOENAsq6ifVitCVH_fprWqeY2398P-tVYuj9gG2T06tl9ffr5aHB_wF9xWt9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2582283529</pqid></control><display><type>article</type><title>The burden of pathogenic variants in clinically actionable genes in a founder population</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 2021&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><creator>Lynch, Megan T. ; Maloney, Kristin A. ; Pollin, Toni I. ; Streeten, Elizabeth A. ; Xu, Huichun ; Shuldiner, Alan R. ; Van Hout, Cristopher V. ; Gonzaga‐Jauregui, Claudia ; Mitchell, Braxton D.</creator><creatorcontrib>Lynch, Megan T. ; Maloney, Kristin A. ; Pollin, Toni I. ; Streeten, Elizabeth A. ; Xu, Huichun ; Shuldiner, Alan R. ; Van Hout, Cristopher V. ; Gonzaga‐Jauregui, Claudia ; Mitchell, Braxton D. ; Regeneron Genetics Ctr ; Regeneron Genetics Center ; Regeneron Genetics Center</creatorcontrib><description>Founder populations may be enriched with certain genetic variants of high clinical impact compared to nonfounder populations due to bottleneck events and genetic drift. Using exome sequencing (ES), we quantified the load of pathogenic variants that may be clinically actionable in 6136 apparently healthy adults living in the Lancaster, PA Old Order Amish settlement. We focused on variants in 78 genes deemed clinically actionable by the American College of Medical Genetics and Genomics (ACMG) or Geisinger's MyCode Health Initiative. ES revealed 3191 total variants among these genes including 480 nonsynonymous variants. After quality control and filtering, we applied the ACMG/AMP guidelines for variant interpretation and classified seven variants, across seven genes, as either pathogenic or likely pathogenic. Through genetic drift, all seven variants, are highly enriched in the Amish compared to nonfounder populations. In total, 14.7% of Lancaster Amish individuals carry at least one of these variants, largely explained by the 13% who harbor a copy of a single variant in APOB. Other studies report combined frequencies of pathogenic/likely pathogenic (P/LP) variants in actionable genes between 2.0% and 6.2% in outbred populations. The Amish population harbors fewer actionable variants compared to similarly characterized nonfounder populations but have a higher frequency of each variant identified, offering opportunities for efficient and cost‐effective targeted precision medicine.</description><identifier>ISSN: 1552-4825</identifier><identifier>EISSN: 1552-4833</identifier><identifier>DOI: 10.1002/ajmg.a.62472</identifier><identifier>PMID: 34467620</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Adult ; Amish - genetics ; Exome - genetics ; exome sequencing ; Female ; founder populations ; Genetic Diseases, Inborn - diagnosis ; Genetic Diseases, Inborn - epidemiology ; Genetic Diseases, Inborn - genetics ; Genetic diversity ; Genetic drift ; Genetic Predisposition to Disease ; Genetic Testing ; Genetic Variation - genetics ; Genetics &amp; Heredity ; genomic medicine ; Genomics ; Humans ; Life Sciences &amp; Biomedicine ; Male ; Middle Aged ; Precision Medicine ; Quality control ; Science &amp; Technology ; secondary findings ; Whole Exome Sequencing</subject><ispartof>American journal of medical genetics. Part A, 2021-11, Vol.185 (11), p.3476-3484</ispartof><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>4</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000691448200001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c3642-5d07e4fdf8809baaed204ac378ab0ebe4375d057dc8957c43f512cbf018df8cf3</citedby><cites>FETCH-LOGICAL-c3642-5d07e4fdf8809baaed204ac378ab0ebe4375d057dc8957c43f512cbf018df8cf3</cites><orcidid>0000-0003-4805-9610 ; 0000-0001-9689-5344 ; 0000-0002-4667-3679</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajmg.a.62472$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajmg.a.62472$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,39263,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34467620$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lynch, Megan T.</creatorcontrib><creatorcontrib>Maloney, Kristin A.</creatorcontrib><creatorcontrib>Pollin, Toni I.</creatorcontrib><creatorcontrib>Streeten, Elizabeth A.</creatorcontrib><creatorcontrib>Xu, Huichun</creatorcontrib><creatorcontrib>Shuldiner, Alan R.</creatorcontrib><creatorcontrib>Van Hout, Cristopher V.</creatorcontrib><creatorcontrib>Gonzaga‐Jauregui, Claudia</creatorcontrib><creatorcontrib>Mitchell, Braxton D.</creatorcontrib><creatorcontrib>Regeneron Genetics Ctr</creatorcontrib><creatorcontrib>Regeneron Genetics Center</creatorcontrib><creatorcontrib>Regeneron Genetics Center</creatorcontrib><title>The burden of pathogenic variants in clinically actionable genes in a founder population</title><title>American journal of medical genetics. Part A</title><addtitle>AM J MED GENET A</addtitle><addtitle>Am J Med Genet A</addtitle><description>Founder populations may be enriched with certain genetic variants of high clinical impact compared to nonfounder populations due to bottleneck events and genetic drift. Using exome sequencing (ES), we quantified the load of pathogenic variants that may be clinically actionable in 6136 apparently healthy adults living in the Lancaster, PA Old Order Amish settlement. We focused on variants in 78 genes deemed clinically actionable by the American College of Medical Genetics and Genomics (ACMG) or Geisinger's MyCode Health Initiative. ES revealed 3191 total variants among these genes including 480 nonsynonymous variants. After quality control and filtering, we applied the ACMG/AMP guidelines for variant interpretation and classified seven variants, across seven genes, as either pathogenic or likely pathogenic. Through genetic drift, all seven variants, are highly enriched in the Amish compared to nonfounder populations. In total, 14.7% of Lancaster Amish individuals carry at least one of these variants, largely explained by the 13% who harbor a copy of a single variant in APOB. Other studies report combined frequencies of pathogenic/likely pathogenic (P/LP) variants in actionable genes between 2.0% and 6.2% in outbred populations. The Amish population harbors fewer actionable variants compared to similarly characterized nonfounder populations but have a higher frequency of each variant identified, offering opportunities for efficient and cost‐effective targeted precision medicine.</description><subject>Adult</subject><subject>Amish - genetics</subject><subject>Exome - genetics</subject><subject>exome sequencing</subject><subject>Female</subject><subject>founder populations</subject><subject>Genetic Diseases, Inborn - diagnosis</subject><subject>Genetic Diseases, Inborn - epidemiology</subject><subject>Genetic Diseases, Inborn - genetics</subject><subject>Genetic diversity</subject><subject>Genetic drift</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic Testing</subject><subject>Genetic Variation - genetics</subject><subject>Genetics &amp; Heredity</subject><subject>genomic medicine</subject><subject>Genomics</subject><subject>Humans</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Precision Medicine</subject><subject>Quality control</subject><subject>Science &amp; Technology</subject><subject>secondary findings</subject><subject>Whole Exome Sequencing</subject><issn>1552-4825</issn><issn>1552-4833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><recordid>eNqN0c9vFCEUB3BibGyt3jwbEi8muis_Z9jjZqPVpsZLTbwRhnm0bFgYYaZm_3vZH-6hh8YTL_B55PEFoTeUzCkh7JNZb-7mZt4w0bJn6IJKyWZCcf78VDN5jl6WsiaEE9k2L9A5F6JpG0Yu0K_be8DdlHuIODk8mPE-3UH0Fj-Y7E0cC_YR2-Drlglhi40dfYqmC4Crg_2xwS5NsYeMhzRMwezEK3TmTCjw-rheop9fPt-uvs5uflx9Wy1vZpY3gs1kT1oQrndKkUVnDPSMCGN5q0xHoAPB20pk21u1kK0V3EnKbOcIVbXHOn6J3h_uHXL6PUEZ9cYXCyGYCGkqmsmmBsAYp5W-e0TXacqxTleVYkxxyRZVfTwom1MpGZwest-YvNWU6F3iepe4NnqfeOVvj5dO3Qb6E_4XcQXqAP5Al1yxHqKFEyOENAsq6ifVitCVH_fprWqeY2398P-tVYuj9gG2T06tl9ffr5aHB_wF9xWt9Q</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Lynch, Megan T.</creator><creator>Maloney, Kristin A.</creator><creator>Pollin, Toni I.</creator><creator>Streeten, Elizabeth A.</creator><creator>Xu, Huichun</creator><creator>Shuldiner, Alan R.</creator><creator>Van Hout, Cristopher V.</creator><creator>Gonzaga‐Jauregui, Claudia</creator><creator>Mitchell, Braxton D.</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4805-9610</orcidid><orcidid>https://orcid.org/0000-0001-9689-5344</orcidid><orcidid>https://orcid.org/0000-0002-4667-3679</orcidid></search><sort><creationdate>202111</creationdate><title>The burden of pathogenic variants in clinically actionable genes in a founder population</title><author>Lynch, Megan T. ; Maloney, Kristin A. ; Pollin, Toni I. ; Streeten, Elizabeth A. ; Xu, Huichun ; Shuldiner, Alan R. ; Van Hout, Cristopher V. ; Gonzaga‐Jauregui, Claudia ; Mitchell, Braxton D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3642-5d07e4fdf8809baaed204ac378ab0ebe4375d057dc8957c43f512cbf018df8cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Amish - genetics</topic><topic>Exome - genetics</topic><topic>exome sequencing</topic><topic>Female</topic><topic>founder populations</topic><topic>Genetic Diseases, Inborn - diagnosis</topic><topic>Genetic Diseases, Inborn - epidemiology</topic><topic>Genetic Diseases, Inborn - genetics</topic><topic>Genetic diversity</topic><topic>Genetic drift</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic Testing</topic><topic>Genetic Variation - genetics</topic><topic>Genetics &amp; Heredity</topic><topic>genomic medicine</topic><topic>Genomics</topic><topic>Humans</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Precision Medicine</topic><topic>Quality control</topic><topic>Science &amp; Technology</topic><topic>secondary findings</topic><topic>Whole Exome Sequencing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lynch, Megan T.</creatorcontrib><creatorcontrib>Maloney, Kristin A.</creatorcontrib><creatorcontrib>Pollin, Toni I.</creatorcontrib><creatorcontrib>Streeten, Elizabeth A.</creatorcontrib><creatorcontrib>Xu, Huichun</creatorcontrib><creatorcontrib>Shuldiner, Alan R.</creatorcontrib><creatorcontrib>Van Hout, Cristopher V.</creatorcontrib><creatorcontrib>Gonzaga‐Jauregui, Claudia</creatorcontrib><creatorcontrib>Mitchell, Braxton D.</creatorcontrib><creatorcontrib>Regeneron Genetics Ctr</creatorcontrib><creatorcontrib>Regeneron Genetics Center</creatorcontrib><creatorcontrib>Regeneron Genetics Center</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of medical genetics. Part A</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lynch, Megan T.</au><au>Maloney, Kristin A.</au><au>Pollin, Toni I.</au><au>Streeten, Elizabeth A.</au><au>Xu, Huichun</au><au>Shuldiner, Alan R.</au><au>Van Hout, Cristopher V.</au><au>Gonzaga‐Jauregui, Claudia</au><au>Mitchell, Braxton D.</au><aucorp>Regeneron Genetics Ctr</aucorp><aucorp>Regeneron Genetics Center</aucorp><aucorp>Regeneron Genetics Center</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The burden of pathogenic variants in clinically actionable genes in a founder population</atitle><jtitle>American journal of medical genetics. Part A</jtitle><stitle>AM J MED GENET A</stitle><addtitle>Am J Med Genet A</addtitle><date>2021-11</date><risdate>2021</risdate><volume>185</volume><issue>11</issue><spage>3476</spage><epage>3484</epage><pages>3476-3484</pages><issn>1552-4825</issn><eissn>1552-4833</eissn><abstract>Founder populations may be enriched with certain genetic variants of high clinical impact compared to nonfounder populations due to bottleneck events and genetic drift. Using exome sequencing (ES), we quantified the load of pathogenic variants that may be clinically actionable in 6136 apparently healthy adults living in the Lancaster, PA Old Order Amish settlement. We focused on variants in 78 genes deemed clinically actionable by the American College of Medical Genetics and Genomics (ACMG) or Geisinger's MyCode Health Initiative. ES revealed 3191 total variants among these genes including 480 nonsynonymous variants. After quality control and filtering, we applied the ACMG/AMP guidelines for variant interpretation and classified seven variants, across seven genes, as either pathogenic or likely pathogenic. Through genetic drift, all seven variants, are highly enriched in the Amish compared to nonfounder populations. In total, 14.7% of Lancaster Amish individuals carry at least one of these variants, largely explained by the 13% who harbor a copy of a single variant in APOB. Other studies report combined frequencies of pathogenic/likely pathogenic (P/LP) variants in actionable genes between 2.0% and 6.2% in outbred populations. The Amish population harbors fewer actionable variants compared to similarly characterized nonfounder populations but have a higher frequency of each variant identified, offering opportunities for efficient and cost‐effective targeted precision medicine.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>34467620</pmid><doi>10.1002/ajmg.a.62472</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4805-9610</orcidid><orcidid>https://orcid.org/0000-0001-9689-5344</orcidid><orcidid>https://orcid.org/0000-0002-4667-3679</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1552-4825
ispartof American journal of medical genetics. Part A, 2021-11, Vol.185 (11), p.3476-3484
issn 1552-4825
1552-4833
language eng
recordid cdi_pubmed_primary_34467620
source MEDLINE; Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />
subjects Adult
Amish - genetics
Exome - genetics
exome sequencing
Female
founder populations
Genetic Diseases, Inborn - diagnosis
Genetic Diseases, Inborn - epidemiology
Genetic Diseases, Inborn - genetics
Genetic diversity
Genetic drift
Genetic Predisposition to Disease
Genetic Testing
Genetic Variation - genetics
Genetics & Heredity
genomic medicine
Genomics
Humans
Life Sciences & Biomedicine
Male
Middle Aged
Precision Medicine
Quality control
Science & Technology
secondary findings
Whole Exome Sequencing
title The burden of pathogenic variants in clinically actionable genes in a founder population
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T09%3A11%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20burden%20of%20pathogenic%20variants%20in%20clinically%20actionable%20genes%20in%20a%20founder%20population&rft.jtitle=American%20journal%20of%20medical%20genetics.%20Part%20A&rft.au=Lynch,%20Megan%20T.&rft.aucorp=Regeneron%20Genetics%20Ctr&rft.date=2021-11&rft.volume=185&rft.issue=11&rft.spage=3476&rft.epage=3484&rft.pages=3476-3484&rft.issn=1552-4825&rft.eissn=1552-4833&rft_id=info:doi/10.1002/ajmg.a.62472&rft_dat=%3Cproquest_pubme%3E2582283529%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2582283529&rft_id=info:pmid/34467620&rfr_iscdi=true